PRODUCTION OFFICE
Marion Laws John Wiley & Sons Ltd, 9600 Garsington Road, Oxford OX4 2DQ, UK febsopenbio@wiley.com
Online ISSN: 2211-5463
This journal is Open Access; all articles will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by a Creative Commons user license: Creative Commons Attribution (CC BY) http://creativecommons. org/licenses/by/4.0/ lets others distribute and copy the article, to remix, transform and build upon the material, to text or data mine the article, even for commercial purposes, as long as they credit the author(s), indicate if changes were made, and do not represent the author as endorsing the adaptation of the article.
Disclaimer The Publisher and Editors cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher and Editors, neither does the publication of advertisements constitute any endorsements by the Publisher and Editors of the products advertised. Wiley Open Access articles posted to repositories or websites are without warranty from Wiley of any kind, either express or implied, including, but not limited to, warranties of merchantability, fitness for a particular purpose, or non-infringement. To the fullest extent permitted by law Wiley disclaims all liability for any loss or damage arising out of, or in connection with, the use of or inability to use the content.
Cover Illustration
Fluorescence micrograph showing zebrafish vasculature. See article on noncanonical function of histidyl-tRNA synthetase: inhibition of vascular hyperbranching during zebrafish development by Rui Ni and Lingfei Luo (722 731).
febsopenbio.org
Volume 8 Number 5
May 2018 ISSN 2211-5463
INFORMATION FOR AUTHORS AIMS AND SCOPE FEBS Open
Bio is an online-only Open Access journal for the rapid publication of research articles in molecular and cellular life sciences in both health and disease. The journalÊs peer review process focuses on the technical soundness of papers, leaving the assessment of their impact and importance to the scientific community. FEBS Open Bio is owned by the Federation of European Biochemical Societies (FEBS, http://www.febs.org), a charity whose objectives are to promote research and education in the molecular life sciences. Any income from the journal will be used to support scientists through fellowships, courses, travel grants, and other FEBS initiatives. FEBS Open Bio publishes experimental findings, critical analysis, methodological and technical innovations, and hypotheses. Novel or innovative work is encouraged, but papers describing sound science of a confirmatory nature in developing fields or extending knowledge of an important topic from one organism to another will also be considered. Articles originally submitted to other FEBS Press publications (FEBS Letters, The FEBS Journal and Molecular Oncology) can be transferred for consideration by FEBS Open Bio with their original reviewer reports, without the need to resubmit or reformat the manuscript.
FEBS Open Bio offers:
• Easy online manuscript submission and tracking system Papers should be submitted using the FEBS Open Bio online submission system, https://mc.manuscriptcentral.com/febsopen. You will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. You are welcome to submit your manuscript as a single file to be used in the peer-review process. Only when your paper reaches final revision stage will you be requested to deliver the individual files in the correct format for publication of your article. Complete information on the journalÊs policies and guidelines for the preparation on manuscripts for submission to the journal can be obtained from http://www.febsopenbio.org or by contacting the editorial office openbio@febs.org OPEN ACCESS PUBLICATION FEE FEBS Open Bio is an Open Access journal with no subscribers. A fee is payable by the author or research funder to cover the costs associated with publication. This ensures each article will be immediately and permanently free for anyone to access. The Open Access publication fee for this journal is $1495, excluding taxes. Authors will be asked to pay the article publication charge on acceptance of their article. Your institute or funder may have an agreement with Wiley to pay all or some of the article publication charge on your behalf. You can check at http://olabout.wiley.com/WileyCDA/Section/id-420429.html. Waivers and discounts are available to authors from countries eligible for the Research4Life programs. You can check the lists of countries at http://www.wileyopenaccess.com/details/content/13707a1ddf6/Waivers-and-Discounts-on-ArticlePublication-Charges.html.
EVALUATION OF MANUSCRIPTS
All submitted manuscripts undergo a technical check in the editorial office to ensure they comply with the journalÊs Guide to Authors. Manuscripts are then assigned to member of the Editorial Board with the appropriate expertise. The handling editor decides whether the article is of sufficient quality for consideration, and if so, invites two expert reviewers. Reviewers are asked to judge whether each paper reports original, primary work, on the soundness of the experimental data and if this data supports the conclusions drawn. The handling editor makes the final decision of whether to accept, reject or invite revision of a manuscript. Our median time to first decision in 2016 was 28 days. For inquiries relating to the submission or reviewing process, please contact: Editorial Office, FEBS Open Bio, 98 Regent Street, Cambridge CB2 1DP, UK. Tel: +44 1223 227708 Email: openbio@febs.org
